<DOC>
	<DOCNO>NCT03019757</DOCNO>
	<brief_summary>The study design characterize clinical , neuropsychological , polysomnographic , neuroimaging finding among subject Alzheimer 's disease , Lewy Body dementia , Parkinsons ' Disease .</brief_summary>
	<brief_title>Distinguishing Between Alzheimer 's Disease , Lewy Body Dementia , Parkinson 's Disease</brief_title>
	<detailed_description>The study use structural functional MRIs , daTscans , fluorodeoxyglucose ( FDG ) PET scan , Amyvid PET scan , polysomnographs , neuropsychological testing , cerebrospinal fluid willing participant distinguish diagnosis Alzheimer 's disease , Lewy Body dementia , Parkinson 's Disease . All subject clinical evaluation , physical examination include vital sign orthostatic blood pressure pulse , neurological examination include UPDRS evaluation , genetic blood sample collection , neuropsychological testing , polysomnogram , neuroimaging . The study partner also interview completion behavioral functional measure .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<criteria>Subjects must meet standard clinical criterion syndromes interest All subject must enough cognitive ability complete study procedure , operationally define Mini Mental State Examination ( MMSE ) score great equal 10 . Subjects must stable cognitive psychoactive medication regimen precede four week enrollment . Subjects must responsible study partner either live regular contact least 4 7 day per week . Subjects must visual auditory acuity adequate testing . Any condition ( primary diagnosis ) , opinion investigator might contribute syndrome dementia complicate assessment . active medical disorder could preclude participation protocol Women pregnant breast feeding severe renal impairment define glomerular filtration rate ( GFR ) less 30 ( may increase radiation exposure DaTscan ) . Subjects English 1st language Subjects educational level le 12 year Subjects ever participate experimental study amyloid target agent unless document subject receive placebo course trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>